Brynn Levy

Prof. Dr. Brynn Levy

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BLBrynn Levy
Brynn Levy
LBLinda B. Baughn
Linda B. Baughn
YAYassmine Akkari
Yassmine Akkari
SCScott Chartrand
Scott Chartrand
BLBrandon LaBarge
Brandon LaBarge
JBJames R. Broach
James R. Broach
Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for diagnostic subtyping, prognosis, and patient management. However, cytogenetic/cytogenomic techniques used to identify those aberrations, such as karyotyping, fluorescence in situ hybridization (FISH), or chromosomal microarray analysis (CMA), are limited by the need for skilled personnel as well as significant time, cost, and labor. Optical genome mapping (OGM) provides a single, cost-effective assay with a significantly higher resolution than karyotyping and with a comprehensive genome-wide analysis comparable with CMA and the added unique ability to detect balanced structural variants (SVs). Here, we report in a real-world setting the performance of OGM in a cohort of 100 AML cases that were previously characterized by karyotype alone or karyotype and FISH or CMA. OGM identified all clinically relevant SVs and copy number variants (CNVs) reported by these standard cytogenetic methods when representative clones were present in >5% allelic fraction. Importantly, OGM identified clinically relevant information in 13% of cases that had been missed by the routine methods. Three cases reported with normal karyotypes were shown to have cryptic translocations involving gene fusions. In 4% of cases, OGM findings would have altered recommended clinical management, and in an additional 8% of cases, OGM would have rendered the cases potentially eligible for clinical trials. The results from this multi-institutional study indicate that OGM effectively recovers clinically relevant SVs and CNVs found by standard-of-care methods and reveals additional SVs that are not reported. Furthermore, OGM minimizes the need for labor-intensive multiple cytogenetic tests while concomitantly maximizing diagnostic detection through a standardized workflow.

17 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
YAYassmine Akkari
Yassmine Akkari
LBLinda B. Baughn
Linda B. Baughn
ADAdrian M. Dubuc
Adrian M. Dubuc
ASAdam Campbell Smith
Adam Campbell Smith
MMM del Mar Mallo
M del Mar Mallo
XXXinjie Xu
Xinjie Xu
Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists, and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, logistic, technical, and financial implications, we provide points to consider for the global evolution of cytogenetic testing.

22 March 2021 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
BLBrynn Levy
Brynn Levy
EHEva R. Hoffmann
Eva R. Hoffmann
RMRajiv C. McCoy
Rajiv C. McCoy
FGFrancesca Romana Grati
Francesca Romana Grati

2 January 2024 in American Journal of Hematology
Verified
Journal Article
Open access
BLBrynn Levy
Brynn Levy
Rashmi Kanagal-ShamannaRashmi Kanagal-Shamanna
Rashmi Kanagal-Shamanna
NSNikhil S. Sahajpal
Nikhil S. Sahajpal
KNKornelia Neveling
Kornelia Neveling
KRKatrina Rack
Katrina Rack
ASAdam Campbell Smith
Adam Campbell Smith
Optical Genome Mapping (OGM) is rapidly emerging as an exciting cytogenomic technology both for research and clinical purposes. In the last 2 years alone, multiple studies have demonstrated that OGM not only matches the diagnostic scope of conventional standard of care cytogenomic clinical testing but it also adds significant new information in certain cases. Since OGM consolidates the diagnostic benefits of multiple costly and laborious tests (e.g., karyotyping, fluorescence in situ hybridization, and chromosomal microarrays) in a single cost-effective assay, many clinical laboratories have started to consider utilizing OGM. In 2021, an international working group of early adopters of OGM who are experienced with routine clinical cytogenomic testing in patients with hematological neoplasms formed a consortium (International Consortium for OGM in Hematologic Malignancies, henceforth "the Consortium") to create a consensus framework for implementation of OGM in a clinical setting. The focus of the Consortium is to provide guidance for laboratories implementing OGM in three specific areas: validation, quality control and analysis and interpretation of variants. Since OGM is a complex technology with many variables, we felt that by consolidating our collective experience, we could provide a practical and useful tool for uniform implementation of OGM in hematologic malignancies with the ultimate goal of achieving globally accepted standards.

23 January 2019 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
BLBrynn Levy
Brynn Levy
RBRachel D. Burnside
Rachel D. Burnside

1 December 2018
Verified
Book Chapter
Closed access
PDF file
BLBrynn Levy
Brynn Levy
MSMelissa Stosic
Melissa Stosic